ReviewPharmaceutics2021
Nanoparticles for Ferroptosis Therapy in Cancer.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 57 citations in OpenAlex.
- Targeting ferroptosis in cancer: molecular mechanisms and emerging therapeutic strategies.Biochemistry and biophysics reports · 2026Review
- Impact of Oxidative Stress-Driven Ferroptosis in Neurodegeneration.International journal of molecular sciences · 2026Review
- Ferroptosis-centered strategies: redefining therapeutic resistance & adaptation in modern oncology.Apoptosis : an international journal on programmed cell death · 2026Review
- Ferroptosis nanomedicine for cancer therapy: strategies and challenges.Frontiers in molecular biosciences · 2026Review
- Ferroptosis and Radiotherapy in Lung Cancer.Cells · 2025Review
- The emerging role of ferroptosis in the pathological development and progression of sepsis.Military Medical Research · 2025Review
- Targeting ferroptosis: a novel pathway in oral, oropharyngeal, hypopharyngeal, and laryngeal cancers.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Exploring the synergetic role of cuproptosis and ferroptosis and their implication in advancing cancer therapeutics.Discover oncology · 2025Review
- Radiation-induced ferroptosis via liposomal delivery of 7-Dehydrocholesterol.Journal of nanobiotechnology · 2025Article
- Nanomaterials targeting iron homeostasis: a promising strategy for cancer treatment.Frontiers in bioengineering and biotechnology · 2025Review
- Silica-Coated SPIONs Induce Ferroptosis in Endothelial Cells While Oleic Acid Mitigates Their Cytotoxic Effects.International journal of nanomedicine · 2025Article
- Nanotheranostics: A Cutting-edge Technology for Cancer Management.Current pharmaceutical biotechnology · 2025Review
- Deubiquitinating enzymes: Key regulators of ferroptosis and pyroptosis and novel targets for cancer intervention.International journal of biological sciences · 2025Review
- Nanoparticle-Mediated Ferroptosis for Cancer Therapy: Mechanisms and Therapeutic Strategies.Nanotechnology, science and applications · 2025Review
- Boosting cancer immunotherapy: drug delivery systems leveraging ferroptosis and immune checkpoint blockade.Frontiers in immunology · 2025Review
- Apoptosis-Cell Cycle-Autophagy Molecular Mechanisms Network in Heterogeneous Aggressive Phenotype Prostate Hyperplasia Primary Cell Cultures Have a Prognostic Role.International journal of molecular sciences · 2024Article
- Tween 80 Micelles Loaded with FePharmaceutics · 2024Article
- Iron (II)-based metal-organic framework nanozyme for boosting tumor ferroptosis through inhibiting DNA damage repair and system XcJournal of nanobiotechnology · 2024Article
- Ferroptosis targeting natural compounds as a promising approach for developing potent liver cancer agents.Frontiers in pharmacology · 2024Review
- Ferroptosis-associated genes and compounds in renal cell carcinoma.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis is a regulated cell death mechanism holding promise for anticancer therapy. Numerous small molecules inducing ferroptosis have been reported thus far. However, these compounds suffer from important drawbacks including poor solubility, systemic toxicity, and scarce tumor targeting ability that have limited their clinical success. The notion that nanoparticles inducing ferroptosis show better preclinical profiles compared to small molecules and overcome resistance to apoptosis has opened a new scenario for cancer treatment. Due to peculiar chemical-physical properties, nanoparticles can be loaded with anticancer drugs or decorated with tumor-selecting molecules. These features allow for drug combination treatment as well as tumor targeting. In the review, we summarize and discuss the available information concerning nanoparticles inducing ferroptosis endowed with different peculiarities and suitable for therapeutic purposes including nanoparticles for (i) antitumor drug delivery, (ii) tumor targeting, (iii) immunomodulation, and (iv) radiofrequency ablation, hyperthermia, and photodynamic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.